Leerink Partners Cuts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $351.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by Leerink Partners from $370.00 to $351.00 in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a market perform rating on the biopharmaceutical company’s stock.

ALNY has been the topic of several other research reports. HC Wainwright set a $570.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, November 4th. Evercore ISI increased their price objective on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an “outperform” rating in a report on Thursday, September 11th. Stifel Nicolaus raised their price objective on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Jefferies Financial Group dropped their target price on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a report on Thursday, October 30th. Finally, BMO Capital Markets increased their price target on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Twenty-three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $477.44.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $392.10 on Monday. The firm has a fifty day moving average of $448.60 and a two-hundred day moving average of $409.30. The firm has a market cap of $51.80 billion, a P/E ratio of 1,633.75 and a beta of 0.30. Alnylam Pharmaceuticals has a 1-year low of $205.87 and a 1-year high of $495.55. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,405 shares of the business’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $635,130.25. Following the completion of the sale, the executive vice president directly owned 27,438 shares of the company’s stock, valued at $12,403,347.90. The trade was a 4.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the firm’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the transaction, the executive vice president owned 54,052 shares in the company, valued at $24,434,206.60. This represents a 6.60% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 60,328 shares of company stock worth $27,288,993. 1.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Root Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $25,000. Salomon & Ludwin LLC acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth $27,000. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth $29,000. Ameriflex Group Inc. bought a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $32,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $36,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.